---
category: news
title: "Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma"
excerpt: "DALLAS, Dec. 17, 2020 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR Â® artificial intelligence (\"A.I.\") platform to transform cancer ..."
publishedDateTime: 2020-12-17T18:53:00Z
originalUrl: "https://www.prnewswire.com/news-releases/lantern-pharma-announces-collaboration-with-world-leading-brain-cancer-program-at-johns-hopkins-to-further-develop-lp-184-as-therapy-for-glioblastoma-301194949.html"
webUrl: "https://www.prnewswire.com/news-releases/lantern-pharma-announces-collaboration-with-world-leading-brain-cancer-program-at-johns-hopkins-to-further-develop-lp-184-as-therapy-for-glioblastoma-301194949.html"
type: article

provider:
  name: PR Newswire
  domain: prnewswire.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://mma.prnewswire.com/media/1216507/Lantern_Pharma_Logo.jpg?p=facebook"
    width: 939
    height: 491
    isCached: true

secured: "oSR7BeO2kxheeuUr4zmfglDKi58qzZmCHFOGZEG4U5oOoK0gnm1gj+ok+moqyTVo1Y08gYwaCLmHOUenGNyHW0GnWxBJalLrw71v7z9Vp+fKu3oxlZxmFv0yWFTgjYuOoaLlHZIIASYiIVh+Y+LMHEN+Yofk/OFXLOU42HkUwOpyE2i7XBhPnKJaeV1VK5JRNlIeCVnk6uJGWYx+kYM8uLPQK/5lGSEXDR9JZNuu5Uux47GewHDSdJ5odGdm3yTt99KiIYCMpOOzyY3NG5PXDHyDNU+NmSDvZd0iHnOoU1YkZvUG7h14GvQpM5PR3OK6bSRM2oJZtNRagAPlSgvTSGYlUoOFQ1xZYqRC11iC3k4=;e0K0ju645v5KFbOxT1qBeg=="
---

